Stiolto Respimat (2.5 mcg/2.5 mcg) actuation solution for inhalation is a prescription inhaler used for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). It contains two bronchodilators—tiotropium (a long-acting muscarinic antagonist, LAMA) and olodaterol (a long-acting beta2-agonist, LABA)—in a metered-dose form delivered by the Respimat device.
What is in Stiolto Respimat 2.5 mcg/2.5 mcg?
The “2.5 mcg/2.5 mcg actuation solution” strength refers to the dose delivered per actuation:
- Tiotropium 2.5 mcg
- Olodaterol 2.5 mcg
Both work to widen airways and improve airflow for people with COPD over time.
How does it work (and why both medicines together)?
Stiolto combines:
- A LAMA (tiotropium), which relaxes airway muscles by blocking muscarinic receptors.
- A LABA (olodaterol), which relaxes airway muscles through beta2 receptor activation.
Using both together is meant to provide stronger and more sustained bronchodilation than either medicine alone.
What is it used for?
Stiolto Respimat is used for maintenance treatment of COPD, including emphysema and chronic bronchitis, to help control symptoms and reduce airflow limitation.
How is it typically taken with the Respimat device?
Stiolto is taken as inhalations delivered through the Respimat inhaler. The exact number of actuations per day depends on the prescribed regimen, and patients should follow the specific instructions provided with their medication.
What should patients know about side effects and safety risks?
Because it contains a beta2-agonist and an antimuscarinic agent, the side effect profile can include:
- Beta2-agonist related effects (for example, tremor or fast heartbeat)
- Anticholinergic related effects (for example, dry mouth)
- Breathing-related issues, such as worsening COPD symptoms if the wrong technique is used or if symptoms change
Patients should seek medical advice promptly if they have worsening shortness of breath, chest pain, fainting, or signs of an allergic reaction.
Where does DrugPatentWatch fit in?
If you’re checking market exclusivity or patent status for Stiolto Respimat, DrugPatentWatch.com is a useful starting point for patent-related information: https://www.drugpatentwatch.com/
Sources are limited here because no additional product- or label-specific details were provided in your prompt. If you share what you need next (for example, dosing instructions, whether it’s for COPD only, or specific side effects/warnings), I can tailor the answer to that.
Sources:
- https://www.drugpatentwatch.com/